Form 4: Zevra Therapeutics Director Thomas Anderson Granted 30,000 Stock Options as Board Compensation

Zevra Therapeutics, Inc. announced that Director Thomas Anderson was granted 30,000 stock options with an exercise price of $8.62 as compensation for his board service, aligning his interests with shareholder value.

Summary

• Thomas Anderson, a Director of Zevra Therapeutics, Inc. (ZVRA), was granted 30,000 stock options.
• The options have an exercise price of $8.62 per share, which was the closing price of the Issuer's common stock on the Nasdaq Global Select Market on the grant date.
• This grant was awarded as compensation for Mr. Anderson's service on the Issuer's board of directors.
• The compensation is pursuant to the Issuer's tenth amended and restated non-employee director compensation policy.
• The options will vest 100% on the earliest of: (i) the first anniversary of the grant date (May 29, 2026), (ii) the date one day prior to the first annual stockholders meeting after the grant date, or (iii) immediately prior to a change in control of the Issuer, subject to continued service.

Sentiment

Score: 7

Explanation: The document reports a routine and positive corporate governance event where a director receives compensation in the form of stock options, aligning their interests with the company's long-term performance. This is a standard practice and does not indicate any negative operational or financial issues.

Positives

• The grant of stock options aligns the director's financial interests with those of the shareholders, incentivizing long-term value creation.
• It represents a standard form of compensation for non-employee directors, ensuring continued experienced oversight for the company.

Future Outlook

The vesting schedule for the granted stock options indicates an expectation of Thomas Anderson's continued service on the board of directors for at least one year, or until a change in control or the next annual stockholders meeting, aligning his future commitment with the company's performance.

Management Comments

• The grant was awarded as compensation for the Reporting Person's service on the Issuer's board of directors pursuant to the Issuer's tenth amended and restated non-employee director compensation policy.

Industry Context

The granting of stock options to non-employee directors is a common and widely accepted practice across various industries, particularly in the biotechnology and pharmaceutical sectors like Zevra Therapeutics. This method of compensation is designed to align the interests of the board members with those of the shareholders, encouraging long-term strategic decisions that enhance company value.

Comparison to Industry Standards

• Granting stock options to non-employee directors is a standard compensation practice across publicly traded companies, including those in the biotechnology sector, to align director interests with shareholder value.
• The exercise price being set at the closing price of the common stock on the grant date ($8.62) is a typical and transparent method for valuing such compensation.
• The vesting schedule, which includes a one-year anniversary or prior to the next annual meeting, is also a common structure for director equity grants, ensuring continued commitment and service.

Corporate Governance

Related Party Transactions

• The grant of 30,000 stock options to Thomas Anderson, a director of Zevra Therapeutics, Inc., constitutes a related party transaction as it involves compensation provided by the company to a member of its board of directors.

Stakeholder Impact

• Shareholders: The grant of stock options to a director aims to align the director's interests with shareholder value, potentially leading to decisions that benefit long-term stock performance.
• Director (Thomas Anderson): Receives equity-based compensation for his service, providing a direct financial incentive tied to the company's stock performance.

Next Steps

• Thomas Anderson's continued service on the board of directors.
• Vesting of the 30,000 stock options based on the specified conditions (first anniversary of grant, day prior to first annual stockholders meeting, or immediately prior to a change in control).

Key Dates

Keywords

ZEVRA THERAPEUTICS, ZVRA, Stock Options, Director Compensation, Form 4, Insider Transaction, Equity Grant, Corporate Governance